Who are Epi Biologics's investors?

Epi Biologics's investors include Avego BioScience Capital, GV (Google Ventures), Mission Biocapital, Novartis Venture Fund, Roche Venture Fund, Samsara BioCapital, Taiho Ventures, LLC, Vivo Capital and 3 more.

How much funding has Epi Biologics raised?

Epi Biologics has disclosed $73M raised across 1 round.

Where is Epi Biologics headquartered?

Epi Biologics is headquartered in San Mateo, US.

Epi Biologics

San Mateo, US · Founded 2021 · 50 employees on LinkedIn · 11 known investors

Find your way into Epi Biologics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Epi Biologics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

Biotech Medical Devices

Founders & leadership

Ann Lee-Karlon CEO, President, and Board MemberShe previously served as COO at Altos Labs, where she helped scale the company to 500 employees, and spent 18 years at Genentech as Senior Vice President overseeing portfolio strategy and project leadership for over 80 drug development programs, including Ocrevus and Rituxan.

Mitchell MutzNamed on SEC filing

James WellsNamed on SEC filing

Board

Samuel Bjork Board directorPartner at Digitalis Ventures

Alexandra Cantley Board MemberManaging Partner at Polaris Partners

Seiji Miyahara Board MemberSenior Investment Director at Taiho Ventures, LLC

Michael KavanaughFounding Advisor

Jason ColomaBoard director

Investors · 11

Avego BioScience Capitallisted by Avego BioScience CapitalAlpharetta

How we know: Avego BioScience Capital's portfolio page · Not right? Tell us

GV (Google Ventures)listed by GV (Google Ventures)Mountain View · $250K – $50M

How we know: GV (Google Ventures)'s portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

Mission Biocapitallisted by Mission BiocapitalSan Francisco · $500K

How we know: Mission Biocapital's portfolio page · the VCSheet dataset · Not right? Tell us

Novartis Venture Fundlisted by Novartis Venture FundBasel · $5M – $25M

How we know: Novartis Venture Fund's portfolio page · Not right? Tell us

Roche Venture Fundlisted by Roche Venture FundBasel · $648K – $3.2M

How we know: Roche Venture Fund's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Samsara BioCapitallisted by Samsara BioCapitalMenlo Park

How we know: Samsara BioCapital's portfolio page · Not right? Tell us

Taiho Ventures, LLClisted by Taiho Ventures, LLCMenlo Park

Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Digitalis VenturesreportedNew York · $100K – $10M

How we know: a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

MPM BioImpactreportedBoston · $1M – $15M

How we know: a partner's Signal profile · Not right? Tell us

Polaris PartnersreportedBoston · $500K – $5Mvia Alexandra Cantley · board

How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$73M disclosed across 1 round · 2022

▶$73MraisedApr 2024 · 15 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Jason ColomaDirector
Ann Lee-KarlonExecutive Officer, Director
Samuel BjorkDirector
Alexandra CantleyDirector
Mitchell MutzExecutive Officer, Director
Seiji MiyaharaDirector
James WellsDirector

Offering amount: $73M
Amount sold: $73M
First sale: Mar 2022
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 6

AbiologicsAbiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.

PeptilogicsPeptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections. Its lead candidate is in a pivotal Phase 2/3 trial and holds FDA Orphan Disease, Fast Track, and QIDP designations.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Epicrispr BiotechnologiesEpic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines. The company serves the biotech/medtech sector with advanced tools for precise gene expression control and disease treatment.

Epics TherapeuticsEPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.

Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Companies working in the same space as Epi Biologics.

Frequently asked questions

What does Epi Biologics do?: Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
Who are Epi Biologics's investors?: Epi Biologics's investors include Avego BioScience Capital, GV (Google Ventures), Mission Biocapital, Novartis Venture Fund, Roche Venture Fund, Samsara BioCapital, Taiho Ventures, LLC, Vivo Capital and 3 more.
How much funding has Epi Biologics raised?: Epi Biologics has disclosed $73M raised across 1 round.
Where is Epi Biologics headquartered?: Epi Biologics is headquartered in San Mateo, US.